🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This medication, which is also used to treat urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This milestone represents a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Results and Worldwide Availability

According to data published in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This establishes an comparable level with the typical regimen, which uses a dual-drug approach. The study included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced optimism. Access to a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is deemed essential to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.